Diagnos

What Diagnos does

DIAGNOS Inc. is a Canadian medical AI company headquartered in Brossard, Quebec, that develops and commercializes the CARA System, an AI platform for analyzing retinal (fundus) photographs to enable early detection of eye diseases such as diabetic retinopathy, age-related macular degeneration, and glaucoma, as well as systemic conditions detectable through retinal imaging. The technology is built on proprietary deep learning and computer vision models applied to standard fundus camera images, allowing integration into existing clinical optometry workflows without specialized hardware. The product portfolio includes the CARA System (core clinical product), FLAIRE (a complementary AI eye health diagnostics platform), Nova Cloud Platform (real-time cloud-based image analysis), and the legacy RetinaCare product line.

The company generates revenue through enterprise agreements with clinics and hospital networks and channel partnerships with major optical industry players - notably EssilorLuxottica and IRIS - distributing CARA across global clinic and retail optical networks. Internationally, DIAGNOS operates a cloud-based deployment model that supports its footprint of 235 equipped centers, 140 clinics across 16 countries, and assessment of over 400,000 patients to date. Regulatory positioning includes cleared commercialization in the United States (legacy CARA), pending Health Canada Class II license submission (June 2026), and pending Saudi Arabia SFDA review (January 2026).

DIAGNOS is publicly traded on the TSX Venture Exchange (ADK) and OTCQB (DGNOF), with reported headcount of 11-50 employees. Its strategic posture emphasizes an academic-industry hybrid model: an AI research collaboration with École de Technologie Supérieure (ÉTS) secured over C$1.0 million in federal funding in February 2026 to advance next-generation retinal AI algorithms under a dedicated research chair. Multiple private placements in late 2025 (totaling approximately C$6 million) are funding regulatory, product development, and commercial initiatives ahead of anticipated multi-jurisdictional approvals.

Name

Diagnos

Legal name

DIAGNOS Inc.

Website

https://diagnos.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

DIAGNOS Inc. is a Canadian medical AI company that commercializes the CARA platform, using deep learning to analyze retinal images for early detection of eye diseases and systemic conditions, serving optometry clinics, hospital networks, and optical industry partners such as EssilorLuxottica across 16 countries.

Ownership category

akta.pro rank

Product category

AI Medical Imaging & Diagnostics

NAICS

Software Publishers (5132)

SIC

Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB), Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)

Keywords

• AI retinal diagnostics
• Ophthalmology screening
• Medical image analysis
• Diabetic retinopathy detection
• Fundus photography AI

Headquarters

HQ city

Brossard

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. AI-based health screening services: DIAGNOS generates revenue through the commercialization of its AI-powered eye disease detection platform (CARA System), providing analysis services to clinical and hospital partners. The company is pursuing regulatory approvals in multiple jurisdictions to enable broad commercial deployment.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

DIAGNOS develops and commercializes the CARA System, an AI-powered retinal image analysis platform that uses deep learning and computer vision to detect eye diseases (diabetic retinopathy, age-related macular degeneration, glaucoma) and systemic conditions from standard fundus camera images. The platform is deployed via cloud-based real-time analysis across optometry clinics, hospital networks, and optical retail partners in 16 countries.

Product overview

DIAGNOS offers a unified AI healthcare platform centered on the CARA retinal analysis system, which detects eye diseases through fundus photography. The portfolio includes the FLAIRE AI platform for broader eye health diagnostics and the Nova Cloud Platform for real-time cloud-based image processing. These products work together to provide early detection of retinal diseases, with CARA serving as the primary clinical product and the other platforms supporting distribution and analysis capabilities across 140+ clinics in 16 countries.

Differentiator

Problem solved

Functional benefit

Brands

• CARA: AI-powered platform for early detection of eye diseases through fundus photography image analysis, used for retinal disease detection and systemic condition screening across clinical optometry workflows.
• FLAIRE
• RetinaCare

Products and services

• CARA System AI-powered retinal analysis platform that detects retinal diseases (diabetic retinopathy, age-related macular degeneration, glaucoma) and systemic conditions from standard fundus camera images, integrated directly into clinical optometry workflows. Deployed in 140+ clinics across 16 countries.
• Nova Cloud Platform Cloud-based real-time medical analysis platform enabling remote processing of retinal images, supporting CARA system deployment in clinical environments without requiring on-premise infrastructure.

Quantifiable outcome

• 500,000+ retinal images analyzed to date
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• École de Technologie Supérieure (ÉTS)coreStrategic or Co-development Partner · 5 February 2026DIAGNOS and ÉTS Montréal entered into a research collaboration that secured over C$1.0 million in federal funding in February 2026 to advance next-generation retinal AI algorithms. The partnership includes the establishment of a dedicated AI research chair at ÉTS, led by Dr. Ismail Ben Ayed, DIAGNOS's Chief AI Scientist. The collaboration drives innovation in AI models for medical image analysis, with published clinical validation across multiple sites.
• EssilorLuxotticacoreChannel Partner/ Reseller/ DistributorDIAGNOS has an established business relationship with EssilorLuxottica, one of the world's largest optical companies, to distribute its CARA AI platform through the company's global clinic and optical retail network. The partnership is part of DIAGNOS's strategy to achieve large-scale commercial deployment through industry leaders.
• IRIScoreChannel Partner/ Reseller/ DistributorDIAGNOS has a business relationship with IRIS for distribution of AI-powered retinal analysis technology through IRIS's network of eye care clinics and optical retail locations, enabling market expansion through established optical distribution channels.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Carl Zeiss Meditec: Global leader in ophthalmic devices and diagnostic instruments with growing AI/data portfolio. Represents the resource-rich incumbent that DIAGNOS competes against for clinical adoption.
• Verily (Alphabet): Alphabet-owned health technology company with retinal AI/diabetic retinopathy programs and deep learning expertise. Represents well-capitalized AI competition in retinal screening.
• Optos (Nikon): Manufacturer of ultra-widefield retinal imaging devices now owned by Nikon. Competes in the retinal imaging workflow where CARA sits as the AI analysis layer.
• Topcon Healthcare: Major ophthalmic device manufacturer (OCT, fundus cameras) integrating AI capabilities into its imaging ecosystem. Larger incumbent competing for the same clinical workflows as CARA.

Direct peers

• Digital Diagnostics (IDx): Pioneer of autonomous AI diagnosis with FDA-cleared IDx-DR for diabetic retinopathy. Direct competitor in the same regulatory and clinical category as CARA.
• AEYE Health: AI startup developing autonomous diabetic retinopathy screening with FDA-cleared products. Comparable target use case (primary care screening) and clinical workflow positioning to DIAGNOS.
• Eyenuk: AI medical device company with FDA-cleared EyeArt system for autonomous diabetic retinopathy screening. Most directly comparable to CARA on disease focus, regulatory pathway, and clinical workflow integration.

Others

• HeartFlow: AI medical imaging company using deep learning for non-invasive cardiovascular diagnostics. Comparable as a regulated AI imaging SaMD company with similar regulatory, reimbursement, and clinical adoption dynamics to CARA.

Emerging players

• Zebra Medical Vision (Nanox): AI medical imaging company (now part of Nanox) developing deep learning algorithms across multiple imaging modalities. Adjacent AI/ML imaging competitor with broader radiology footprint.
• Retina-AI Health: Emerging AI company focused on retinal disease detection from fundus and OCT images. Direct niche overlap with CARA but at an earlier commercialization stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/diagnosmedical
• Facebookfacebook.com/diagnosmedical
• LinkedInlinkedin.com/company/diagnosmedical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds19 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diagnos